scholarly journals None Budgetary Forms of Health Funding in the KR

2018 ◽  
Author(s):  
Damira Japarova
Keyword(s):  
Medical Service ◽  
Regulatory Mechanism ◽  
Market Price ◽  
Complete Recovery ◽  
Point Of View ◽  
Preferential Treatment ◽  
Informal Payment ◽  
Health Funding ◽  
Cost Of Drugs ◽  
The Cost

In Kyrgyzstan, significant share of the state funds used on the preferential treatment and financing of treatment other patients largely tolerated by themselves. However, the replacement of free services with paid ones occurs spontaneously and haphazardly. The strategy of replacement of free Medicare to paid in official documents and normative acts are not formulated, however, it really exists. With the introduction of co- payment system, patients are forced repeatedly pay for the same medical service, eventually not having a warranty for complete recovery. Many administrators in medicine believe that they do not need to take co-payment from patients, because the patients buying medicines themselves, and in this regard, there are many claims and perturbations on this subject. Our point of view, informal payments in medicine, i.e., unofficial payments to the doctor should not be seen as a "bribe". In the absence of a regulatory mechanism, the informal payment for services acts as a state-nonregulated addition to the market price, this cannot be canceled or destroyed. The only way to put them to some kind of framework - is legalization these payments. Special funds, or receipts from paid services should become a source of own fund of a polyclinic or hospital, which can be used first of all for increasing the salaries of medical workers. Instead of fixed co-payments in medical care, it is advisable to introduce co-payment in relation to medicines, i.e. pay part of the cost of drugs used in the treatment of the patient.

scholarly journals Diagnostics of Financing the System of Public Health in the Kyrgyzstan Republic and its Modernization

2020 ◽  
Author(s):  
Damira Japarova
Keyword(s):  
Medical Service ◽  
Regulatory Mechanism ◽  
Market Price ◽  
Health Financing ◽  
Health Needs ◽  
Health Programs ◽  
Kyrgyz Republic ◽  
Health Organizations ◽  
Compulsory Health Insurance ◽  
Insured Patient

Despite the multi-channel resources, the financial sources of state health programs do not cover the needs of their implementation in the Kyrgyz Republic. The residual principle of health financing keeps unchanged and the amount of financing does not match the real health needs. The variety of problems in financing, the ambiguity of their positive practical solutions and controversy of theoretical aspects makes the research topic particularly relevant. No funds are allocated for prevention, and this type of medical service remains formally, just on paper. The main drawback of compulsory health insurance is the lack of forms for the insured patient to participate in the economic system of insurance relations. In this connection, it is relevant to develop a mechanism for attracting additional sources of financing. To increase the interest of commercial structure to this structure, it is proposed to introduce personalized accounting of compulsory medical insurance. Informal payments in medicine shouldn’t be considered as a “bribe”, since this type of payment for medical services acts as an addition to the market price in the absence of an adequate regulatory mechanism by the state, and it is impossible to cancel such a mechanism. The only way to formalize them is legalization. Revenues from paid services should be the source of the own fund of health organizations and used primarily to increase the salaries of medical workers.

scholarly journals Clinical trials and drug cost savings for Italian health service

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Francesca D’Ambrosio ◽  
Gianfranco De Feo ◽  
Gerardo Botti ◽  
Arturo Capasso ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Health Service ◽  
Market Price ◽  
Cost Savings ◽  
Antineoplastic Drugs ◽  
Experimental Drugs ◽  
Cost Of Drugs ◽  
The Cost ◽  
The Impact

Abstract Background The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials. Methods We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. Results From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5487 Euros saved per patients for a period of 4 weeks. Conclusions Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.

scholarly journals Metanalysis Economical-Financial Performance of the Production of Milk and Goats on Systems of Family Farming

2020 ◽  
Vol 8 (4) ◽  
pp. 360
Author(s):  
Olivan Cunha de Almeida ◽  
Ricardo Alves de Araújo ◽  
Luiza De Nazaré Carneiro da Silva ◽  
Edmilson Igor Bernardo Almeida ◽  
Khalil De Menezes Rodrigues ◽  
...  
Keyword(s):  
Return On Investment ◽  
Financial Analysis ◽  
Meta Analysis ◽  
Market Price ◽  
Point Of View ◽  
Dairy Goats ◽  
Family Farming ◽  
Technical Parameters ◽  
The Creation ◽  
The Cost

This study aimed to evaluate the economic and financial viability of the creation of dairy goats of Saanen breed and Anglo Nubian in system of family farming. The information of the technical parameters for financial analysis of this research were obtained in manuscripts the published in the last ten years in national journals. In face of these data was conducted a meta-analysis of data which generated the zootechnical date used for the simulations in this work. The simulation for milk production and calves from 72 dairy goats provided revenue above the cost of production, resulting in positive economic indicators for both scenarios assessed. The revenue generated by the systems that utilize the Saanen goats are bigger, considering that the production is greater. The financial analysis of systems proved to be viable over 8 years. In relation to the payback, both presented low return on investment applied. Sensitivity analyzes showed that in both systems evaluated, only in the most unfavorable situations, such as a reduction of 30% in both production and market price, the indicators of economic performance are not attractive, given that the time of return on investment is too long, especially in the rearing of goats Anglo Nubian. From the practical point of view, it is recommended the creation of both breeds, because the cost of deployment of the system can be purchased via funding.

scholarly journals Clinical trials and drug cost savings for Italian Health Service

2020 ◽  
Author(s):  
Francesca D’Ambrosio ◽  
Gianfranco De Feo ◽  
Gerardo Botti ◽  
Arturo Capasso ◽  
Sandro Pignata ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Practice ◽  
Health Service ◽  
Market Price ◽  
Cost Savings ◽  
Antineoplastic Drugs ◽  
Experimental Drugs ◽  
Cost Of Drugs ◽  
The Cost ◽  
The Impact

Abstract Background: The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials.Methods: We evaluated the cost of drugs administered to patients treated in clinical trials at the National Cancer Institute of Naples in a four-week time period. Patients with a diagnosis of different cancers were considered, including adjuvant therapy and treatment for advanced disease, pharma sponsored and investigator initiated phase I, II and III clinical studies. We defined the expected standard treatment for each patient and we calculated the cost of the standard antineoplastic drugs that should be administered in clinical practice outside clinical trials. We used the market price of drugs to determine the cost savings value. Costs other than drugs were not included in the cost saving calculation. Results: From 23.10.2017 to 17.11.2017, 126 patients were treated in 34 pharma sponsored and investigator initiated clinical trials, using experimental drugs provided free of charge by the sponsors, for an overall number of 152 cycles of therapy. If these patients were treated with conventional therapies in clinical practice the cost of antineoplastic drugs would account for 517,658 Euros, with an average of 5,487 Euros saved per patients for a period of four weeks.Conclusions: Clinical trials with investigational antineoplastic drugs provided free of charge by Sponsors render considerable cost savings, with a tangible benefit in clinical and administrative strategies to reduce drug expenditures.

Evaluation Of The Functional Of Space-Planning Arrangement Of A Building

2019 ◽  
pp. 4-9
Keyword(s):  
Numerical Simulation ◽  
Life Cycle ◽  
Initial Data ◽  
Objective Assessment ◽  
Objective Evaluation ◽  
Point Of View ◽  
Shopping Centers ◽  
Space Planning ◽  
Planning Decisions ◽  
The Cost

The article focuses on the problem of the lack of objective evaluation of space-planning arrangement of buildings as a creative approach of the architect to the performing of functional tasks by the object. It is proposed to create a methodology for assessing the functional of space-planning solutions of buildings on the basis of numerical simulation of functional processes using the theory of human flows. There is a description of the prospects of using this method, which makes it possible to increase the coefficient of compactness, materials and works saving, more efficient use of space, reduce the cost of the life cycle of the building, save human forces and time to implement the functional of the building. The necessary initial data for modeling on the example of shopping and shopping-entertainment centers are considered. There are three main tasks for algorithmization of the functional of shopping centers. The conclusion is made about necessity of development of a method for objective assessment of buildings from the point of view of ergonomics of space-planning decisions based on the study of human behavior in buildings of different purposes.

PREREQUISITES FOR THE FORMATION OF A MECHANISM FOR STATE REGULATION OF SOCIAL GUARANTEES IN THE REGION

2017 ◽  
Author(s):  
Vitaly Lobas ◽  
◽  
Elena Petryaeva ◽  
Keyword(s):  
Social Protection ◽  
Well Being ◽  
State Regulation ◽  
The State ◽  
Point Of View ◽  
Periodic Review ◽  
Cost Of Living ◽  
Economic Relations ◽  
State Management ◽  
The Cost

The article deals with modern mechanisms for managing social protection of the population by the state and the private sector. From the point of view of forms of state regulation of the sphere of social protection, system indicators usually include the state and dynamics of growth in the standard of living of the population, material goods, services and social guarantees for the poorly provided segments of the population. The main indicator among the above is the state of the consumer market, as one of the main factors in the development of the state. Priority areas of public administration with the use of various forms of social security have been identified. It should be emphasized that, despite the legislative conflicts that exist today in Ukraine, mandatory indexation of the cost of living is established, which is associated with inflation. Various scientists note that although the definition of the cost of living index has a well-established methodology, there are quite a lot of regional features in the structure of consumption. All this is due to restrictions that are included in the consumer basket of goods and different levels of socio-economic development of regions. The analysis of the establishment and periodic review of the minimum consumer budgets of the subsistence minimum and wages of the working population and the need to form state insurance funds for unforeseen circumstances is carried out. Considering in this context the levers of state management of social guarantees of the population, we drew attention to the crisis periods that are associated with the market transformation of the regional economy. In these conditions, there is a need to develop and implement new mechanisms and clusters in the system of socio-economic relations. The components of the mechanisms ofstate regulation ofsocial guarantees of the population are proposed. The deepening of market relations in the process of reforming the system of social protection of the population should be aimed at social well-being.

scholarly journals Inclusionary Housing: An Evaluation of a New Public Rental Housing Governance Instrument in China

Land ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 305
Author(s):  
Juan Yan ◽  
Marietta Haffner ◽  
Marja Elsinga
Keyword(s):  
Housing Market ◽  
Affordable Housing ◽  
Local Governments ◽  
Rental Housing ◽  
Analytical Framework ◽  
Point Of View ◽  
Policy Implications ◽  
Research Approach ◽  
Inclusionary Housing ◽  
The Cost

Inclusionary housing (IH) is a regulatory instrument adopted by local governments in many countries to produce affordable housing by capturing resources created through the marketplace. In order to assess whether it is efficient, scholarly attention has been widely focused on its evaluation. However, there is a lack of studies evaluating IH from a governance perspective. Since IH is about involving private actors in affordable housing production, the governance point of view of cooperating governmental and non-governmental actors governing society to achieve societal goals is highly relevant. The two most important elements of governance—actors and interrelationships among these actors—are taken to build an analytical framework to explore and evaluate the governance of IH. Based on a research approach that combines a literature review and a case study of China, this paper concludes that the ineffective governance of Chinese IH is based on three challenges: (1) The distribution of costs and benefits across actors is unequal since private developers bear the cost, but do not enjoy the increments of land value; (2) there is no sufficient compensation for developers to offset the cost; and (3) there is no room for negotiations for flexibility in a declining market. Given that IH is favored in many Chinese cities, this paper offers the policy implications: local governments should bear more costs of IH, rethink their relations with developers, provide flexible compliance options for developers, and perform differently in a flourishing housing market and a declining housing market.

PP581 Catastrophic Costs Of Multidrug-Resistant Tuberculosis: Estimation Based On The Cost Of Treatment In China

2020 ◽  
Vol 36 (S1) ◽  
pp. 43-43
Author(s):  
Lijun Shen ◽  
Shangshang Gu ◽  
Fan Zhang ◽  
Zhao Liu ◽  
Yuehua Liu
Keyword(s):  
Market Price ◽  
Multidrug Resistant ◽  
Policy Support ◽  
World Health ◽  
Chinese Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb ◽  
Drug Affordability ◽  
The Cost

IntroductionChina bears a considerably high burden of multidrug-resistant tuberculosis (MDR-TB). Second-line anti-TB drugs are urgently needed yet domestic MDR-TB drugs are expensive and lack policy support. Patients’ living conditions are closely related to the drug affordability. The national TB prevention programs should play a critical role. The purpose of this study is to measure the cost of treating MDR-TB patients under different treatment schemes and price sources. The results of this study are expected to inform the relevant drug protection policies and provide inputs for further cost-effectiveness analyses.MethodsBased on the treatment plan of China's Multidrug-Resistant Pulmonary Tuberculosis Clinical Path (2012 edition) and the World Health Organization (WHO) Drug-Resistant Tuberculosis Treatment Guide (2018 edition), the treatment costs of MDR-TB were measured under different scenarios. Catastrophic health expenditure was then calculated if the treatment cost exceeds 40 percent of the household's non-subsistence income. National, rural and disposable income per capita in 2018, were used to represent Chinese patients’ affordability.ResultsUnder varied treatment schemes and market price sources in China, the total costs for MDR-TB patients range from 19,401 to 126,703 CNY [2,853 to 18,633 USD] per person. Under current prices, all treatment schemes recommended by the WHO will incur catastrophic costs for Chinese MDR-TB patients. Significant differences were found between rural and urban areas as 52.8 percent of the treatment listed in the 2012 China Guideline would lead to catastrophic cost for rural patients but not urban ones.ConclusionsOur study concludes that the domestic drugs are more expensive than the international purchase price and the treatment of MDR-TB imposes substantial economic burden on patients, especially in the rural areas. The results of the study also indicate that it is urgent for the state to emphasize government responsibility and initiate centralized procurement for price negotiations to reduce the market price of MDR-TB drugs. The urban-rural gap should also be addressed in the design of future policies to ensure the drug affordability for all patients in need.

scholarly journals Backward-forward linear-quadratic mean-field Stackelberg games

2021 ◽  
Vol 2021 (1) ◽  
Author(s):  
Kehan Si ◽  
Zhen Wu
Keyword(s):  
Large Population ◽  
Consistency Condition ◽  
Market Price ◽  
Mean Field ◽  
Mapping Method ◽  
Open Loop ◽  
Stackelberg Games ◽  
Linear Quadratic ◽  
Population System ◽  
The Cost

AbstractThis paper studies a controlled backward-forward linear-quadratic-Gaussian (LQG) large population system in Stackelberg games. The leader agent is of backward state and follower agents are of forward state. The leader agent is dominating as its state enters those of follower agents. On the other hand, the state-average of all follower agents affects the cost functional of the leader agent. In reality, the leader and the followers may represent two typical types of participants involved in market price formation: the supplier and producers. This differs from standard MFG literature and is mainly due to the Stackelberg structure here. By variational analysis, the consistency condition system can be represented by some fully-coupled backward-forward stochastic differential equations (BFSDEs) with high dimensional block structure in an open-loop sense. Next, we discuss the well-posedness of such a BFSDE system by virtue of the contraction mapping method. Consequently, we obtain the decentralized strategies for the leader and follower agents which are proved to satisfy the ε-Nash equilibrium property.

Prescribing costs

1993 ◽  
Vol 31 (22) ◽  
pp. 87-87
Keyword(s):  
General Practitioners ◽  
Average Cost ◽  
Department Of Health ◽  
Cost Of Drugs ◽  
The Cost

The cost of drugs prescribed by general practitioners in England rose by 13.4% between 1991 and 1992, bringing the total amount spent on medicines prescribed in the community last year to £2858 million. In the same period the number of items dispensed rose by 4.6%, or 4.2% per head of population, and the average cost per item increased by 8.5%, from £6.20 to £6.72. These figures are contained in the latest issue of the Statistical Bulletin,1 published annually by the Department of Health.

Sign in / Sign up

Export Citation Format

Share Document